ORIGINAL_ARTICLE
A Tribute to Professor Maike Petersen
Maike Petersen as a professor of pharmaceutical biology at Marburg University has been admired on the occasion of her 62nd birthday. Her scientific trend, mesmerizing character, discipline, and good nature make her a role model for the generation of students and colleagues. Her behavior can profoundly influence the thoughts on scholarship, leadership, and humanity. A rare combination of a personality trait with simultaneous brilliance and humbleness makes her so respected. In addition to all the marvelous attributes of her personality, her reputation as a phytochemist is truly deserved. A brief review of her achievements shows that she is one of the pioneers in the identification and characterization of enzymes, especially in vitro plant cultures, to shed light on the biosynthetic pathways in the way of the production of valuable metabolites. Trends of her research show her focused and oriented investigations in the field. Therefore, within this letter, her commitment to innovation, pluralism, generosity of spirit with all due respect has been admired.
https://tips.sums.ac.ir/article_47133_3a7d2131ffdf2449c7c0ed48293c0daa.pdf
2020-12-01
231
232
10.30476/tips.2020.88890.1071
Professor Maike Petersen
Legacy
Phytochemistry
Shiva
Hemmati
hemmatish@sums.ac.ir
1
Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.
LEAD_AUTHOR
1. Petersen M. Current status of metabolic phytochemistry. Phytochemistry. 2007 Nov-Dec;68(22-24):2847-60. doi: 10.1016/j.phytochem.2007.07.029. Epub 2007 Sep 18. PMID: 17881017.
1
2. Petersen M, Seitz HU. Reconstitution of cytochrome P-450-dependent digitoxin 12 beta-hydroxylase from cell cultures of foxglove (Digitalis lanata EHRH.). Biochem J. 1988 Jun 1;252(2):537-43. doi: 10.1042/bj2520537. PMID: 3137929; PMCID: PMC1149177.
2
3. Petersen M, Alfermann AW. Two new enzymes of rosmarinic acid biosynthesis from cell cultures of Coleus blumei: hydroxyphenylpyruvate reductase and rosmarinic acid synthase. Z Naturforsch C. 1988 Aug 1;43(7-8):501-4.
3
4. Petersen MS. Characterization of rosmarinic acid synthase from cell cultures of Coleus blumei. Phytochemistry. 1991 Jan 1;30(9):2877-81.
4
5. Petersen M, Häusler E, Karwatzki B, Meinhard J. Proposed biosynthetic pathway for rosmarinic acid in cell cultures of Coleus blumei Benth. Planta. 1993 Jan 1;189(1):10-4.
5
6. Petersen M. Cytochrome P450-dependent hydroxylation in the biosynthesis of rosmarinic acid in Coleus. Phytochemistry. 1997 Jul 1;45(6):1165-72.
6
7. Molog G, Empt U, Kuhlmann S, van Uden W, Pras N, Alfermann A, Petersen M. Deoxypodophyllotoxin 6-hydroxylase, a cytochrome P450 monooxygenase from cell cultures of Linum flavum involved in the biosynthesis of cytotoxic lignans. Planta. 2001 Dec 1;214(2):288-94.
7
8. Kranz K, Petersen M. β-Peltatin 6-O-methyltransferase from suspension cultures of Linum nodiflorum. Phytochemistry. 2003 Sep 1;64(2):453-8.
8
9. Berger A, Meinhard J, Petersen M. Rosmarinic acid synthase is a new member of the superfamily of BAHD acyltransferases. Planta. 2006 Nov 1;224(6):1503-10.
9
10. Sander M, Petersen M. Distinct substrate specificities and unusual substrate flexibilities of two hydroxycinnamoyltransferases, rosmarinic acid synthase and hydroxycinnamoyl-CoA: shikimate hydroxycinnamoyl-transferase, from Coleus blumei Benth. Planta. 2011 Jun 1;233(6):1157-71.
10
11. Hücherig S, Petersen M. RNAi suppression and overexpression studies of hydroxyphenylpyruvate reductase (HPPR) and rosmarinic acid synthase (RAS) genes related to rosmarinic acid biosynthesis in hairy root cultures of Coleus blumei. Plant Cell Tiss Organ Cult. 2013 Jun 1;113(3):375-85.
11
ORIGINAL_ARTICLE
Novel heterocyclic hybrid of 2-(aryl)-1H-indene-1,3(2H)-dione targeting tyrosinase: design, biological evaluation and in silico studies
Melanogenesis is a process of melanin synthesize, which is a primary response for the pigmentation of human skin. Tyrosinase is a key enzyme, which catalyzes a rate-limiting step of the melanin formation, natural products have shown potent inhibitors, but some of these possess toxicity. Numerous synthetic inhibitors have been developed in recent years may lead to the potent anti-tyrosinase agents. Therefore its inhibition may be an efficient way for the development of depigmenting agents. A novel series of 2-arylidine-1H-indene-1,3(2H)-dione analogs were designed, synthesized and screened for their in vitro tyrosinase inhibitory activity. 3d derivative bearing nitrothiophene revealed excellent anti-tyrosinase activity with an IC50 value of 3.55 μM comparable to kojic acid as a positive control. 3d as the most potent inhibitor and 3f as the least active derivative were subjected to in silico evaluations considering the 3D conformations, ΔGb of bindings and interactions within the active site of tyrosinase.
https://tips.sums.ac.ir/article_47117_413de650c0a9c47dd1647abf45d85727.pdf
2020-12-01
233
242
10.30476/tips.2020.88203.1068
1
3-Indandione
Tyrosinase inhibitor
In silico studies
organic Synthesis
Aida
Iraji
aida.iraji@gmail.com
1
Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, 71348 Shiraz, Iran Central Research Laboratory, Shiraz University of Medical Sciences, 71468 Shiraz, Iran
AUTHOR
Ali
Nemati
alinemati@yahoo.com
2
b Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, 71345 Shiraz, Iran
AUTHOR
Hona
Hosseinpoor
honahosseinpoor@yahoo.com
3
Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, 71345 Shiraz, Iran
AUTHOR
Najmeh
Edraki
edrakin@sums.ac.ir
4
Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, 71348 Shiraz, Iran
AUTHOR
mahsima
Khoshneviszadeh
mahsimakhoshnevisz@gmail.com
5
Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, 71348 Shiraz, Iran
AUTHOR
Mahshid
Attarroshan
mahshidattar2015@yahoo.com
6
a Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, 71348 Shiraz, Iran
AUTHOR
Hossein
Sadeghpour
sadeghpurh@sums.ac.ir
7
Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, 71345 Shiraz, Iran
AUTHOR
Mehdi
Khoshneviszadeh
khoshnevim@sums.ac.ir
8
Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, 71348 Shiraz, Iran Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, 71345 Shiraz, Iran
LEAD_AUTHOR
1. Zolghadri S, Bahrami A, Hassan Khan MT, et al. A comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2019;34(1):279-309. doi:10.1080/14756366.2018.1545767
1
2. Drescher DG, Selvakumar D, Drescher MJ. Analysis of Protein Interactions by Surface Plasmon Resonance. Adv Protein Chem Struct Biol. 2018;110:1-30. doi: 10.1016/bs.apcsb.2017.07.003. Epub 2017 Sep 12. PMID: 29412994.
2
3. Jus S, Guebitz GM, Kokol V. Enzyme-Catalysed Coupling of Functional Antioxidants onto Protein Fibres. In: Anand SC, Kennedy JF, Miraftab M, Rajendran S, editors. Medical and Healthcare Textiles: Woodhead Publishing; 2010. p. 126-34.
3
4. Jungbluth AA, Busam KJ. 29 - Immunohistochemistry for the Diagnosis of Melanocytic Proliferations. In: Busam KJ, Gerami P, Scolyer RA, editors. Pathology of Melanocytic Tumors. Philadelphia: Elsevier; 2019. p. 348-63.
4
5. Hosseinpoor H, Iraji A, Edraki N, Pirhadi S, Attarroshan M, Khoshneviszadeh M, Khoshneviszadeh M. A Series of Benzylidenes Linked to Hydrazine-1-carbothioamide as Tyrosinase Inhibitors: Synthesis, Biological Evaluation and Structure-Activity Relationship. Chem Biodivers. 2020 Aug;17(8):e2000285. doi: 10.1002/cbdv.202000285. Epub 2020 Aug 3. PMID: 32478439.
5
6. Iraji A, Khoshneviszadeh M, Bakhshizadeh P, Edraki N, Khoshneviszadeh M. Structure-Based Design, Synthesis, Biological Evaluation and Molecular Docking Study of 4-Hydroxy-N'-methylenebenzohydrazide Derivatives Acting as Tyrosinase Inhibitors with Potentiate Anti-Melanogenesis Activities. Med Chem. 2020;16(7):892-902. doi: 10.2174/1573406415666190724142951. PMID: 31339074.
6
7. Messerschmidt A. 8.14 - Copper Metalloenzymes. In: Liu H-W, Mander L, editors. Comprehensive Natural Products II. Oxford: Elsevier; 2010. p. 489-545.
7
8. Karimian S, Ranjbar S, Dadfar M, Khoshneviszadeh M, Gholampour M, Sakhteman A, Khoshneviszadeh M. 4H-benzochromene derivatives as novel tyrosinase inhibitors and radical scavengers: synthesis, biological evaluation, and molecular docking analysis. Mol Divers. 2020 Jul 18. doi: 10.1007/s11030-020-10123-0. Epub ahead of print. PMID: 32683615.
8
9. Lolak N, Boga M, Tuneg M, Karakoc G, Akocak S, Supuran CT. Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile. J Enzyme Inhib Med Chem. 2020 Dec;35(1):424-431. doi: 10.1080/14756366.2019.1707196. PMID: 31899985; PMCID: PMC6968691.
9
10. Ranjbar S, Shahvaran PS, Edraki N, Khoshneviszadeh M, Darroudi M, Sarrafi Y, Hamzehloueian M, Khoshneviszadeh M. 1,2,3-Triazole-linked 5-benzylidene (thio)barbiturates as novel tyrosinase inhibitors and free-radical scavengers. Arch Pharm (Weinheim). 2020 Oct;353(10):e2000058. doi: 10.1002/ardp.202000058. Epub 2020 Jul 8. PMID: 32638438.
10
11. Hałdys K, Goldeman W, Jewgiński M, Wolińska E, Anger-Góra N, Rossowska J, Latajka R. Halogenated aromatic thiosemicarbazones as potent inhibitors of tyrosinase and melanogenesis. Bioorg Chem. 2020 Jan;94:103419. doi: 10.1016/j.bioorg.2019.103419. Epub 2019 Nov 9. PMID: 31761412.
11
12. Iraji A, Adelpour T, Edraki N, Khoshneviszadeh M, Miri R, Khoshneviszadeh M. Synthesis, biological evaluation and molecular docking analysis of vaniline-benzylidenehydrazine hybrids as potent tyrosinase inhibitors. BMC Chem. 2020 Apr 7;14(1):28. doi: 10.1186/s13065-020-00679-1. PMID: 32280949; PMCID: PMC7137441.
12
13. Patravale AA, Gore AH, Kolekar GB, Deshmukh MB, Choudhari PB, Bhatia MS, et al. Synthesis, biological evaluation and molecular docking studies of some novel indenospiro derivatives as anticancer agents. J Taiwan Inst Chem Eng. 2016;68:105-18.
13
14. Beck DE, Lv W, Abdelmalak M, Plescia CB, Agama K, Marchand C, Pommier Y, Cushman M. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons. Bioorg Med Chem. 2016 Apr 1;24(7):1469-79. doi: 10.1016/j.bmc.2016.02.015. Epub 2016 Feb 9. PMID: 26906474; PMCID: PMC4789169.
14
15. Fadda A, Khalil A, Tawfik E. Enaminonitriles in heterocyclic synthesis: Synthesis and biological evaluation of novel indeno[2,1-b]thiophene derivatives.Turk J Chem. 2013;37:134-48.
15
16. Khalifa NM, Al-Omar MA, Amr AE-GE, Baiuomy AR, Abdel-Rahman RF. Synthesis and biological evaluation of some novel fused thiazolo[3,2-a]pyrimidines as potential analgesic and anti-inflammatory agents. Bioorg Khim. 2015 Mar-Apr;41(2):218-26. doi: 10.7868/s0132342315020098. PMID: 26165129.
16
17. Catto M, Aliano R, Carotti A, Cellamare S, Palluotto F, Purgatorio R, De Stradis A, Campagna F. Design, synthesis and biological evaluation of indane-2-arylhydrazinylmethylene-1,3-diones and indol-2-aryldiazenylmethylene-3-ones as beta-amyloid aggregation inhibitors. Eur J Med Chem. 2010 Apr;45(4):1359-66. doi: 10.1016/j.ejmech.2009.12.029. Epub 2009 Dec 23. PMID: 20137834.
17
18. Khan G, Aftab MF, Bano B, Khan KM, Murtaza M, Siddiqui S, Rehman MH, Waraich RS. A new indanedione derivative alleviates symptoms of diabetes by modulating RAGE-NF-kappaB pathway in db/db mice. Biochem Biophys Res Commun. 2018 Jul 2;501(4):863-870. doi: 10.1016/j.bbrc.2018.05.043. Epub 2018 May 21. PMID: 29778537.
18
19. Iraji A, Firuzi O, Khoshneviszadeh M, Nadri H, Edraki N, Miri R. Synthesis and structure-activity relationship study of multi-target triazine derivatives as innovative candidates for treatment of Alzheimer's disease. Bioorg Chem. 2018 Apr;77:223-235. doi: 10.1016/j.bioorg.2018.01.017. Epub 2018 Jan 16. PMID: 29367079.
19
20. Yazdani M, Edraki N, Badri R, Khoshneviszadeh M, Iraji A, Firuzi O. Multi-target inhibitors against Alzheimer disease derived from 3-hydrazinyl 1,2,4-triazine scaffold containing pendant phenoxy methyl-1,2,3-triazole: Design, synthesis and biological evaluation. Bioorg Chem. 2019 Mar;84:363-371. doi: 10.1016/j.bioorg.2018.11.038. Epub 2018 Nov 29. PMID: 30530107.
20
21. Iraji A, Nouri A, Edraki N, Pirhadi S, Khoshneviszadeh M, Khoshneviszadeh M. One-pot synthesis of thioxo-tetrahydropyrimidine derivatives as potent β-glucuronidase inhibitor, biological evaluation, molecular docking and molecular dynamics studies. Bioorg Med Chem. 2020 Apr 1;28(7):115359. doi: 10.1016/j.bmc.2020.115359. Epub 2020 Feb 6. PMID: 32098709.
21
22. Kim YJ. Rhamnetin attenuates melanogenesis by suppressing oxidative stress and pro-inflammatory mediators. Biol Pharm Bull. 2013;36(8):1341-7. doi: 10.1248/bpb.b13-00276. Epub 2013 Jun 4. PMID: 23739488.
22
23. Ismaya WT, Rozeboom HJ, Weijn A, Mes JJ, Fusetti F, Wichers HJ, Dijkstra BW. Crystal structure of Agaricus bisporus mushroom tyrosinase: identity of the tetramer subunits and interaction with tropolone. Biochemistry. 2011 Jun 21;50(24):5477-86. doi: 10.1021/bi200395t. Epub 2011 May 27. PMID: 21598903.
23
24. Lee TH, Seo JO, Baek SH, Kim SY. Inhibitory effects of resveratrol on melanin synthesis in ultraviolet B-induced pigmentation in Guinea pig skin. Biomol Ther (Seoul). 2014;22(1):35-40. doi:10.4062/biomolther.2013.081
24
25. Pillaiyar T, Namasivayam V, Manickam M, Jung SH. Inhibitors of Melanogenesis: An Updated Review. J Med Chem. 2018 Sep 13;61(17):7395-7418. doi: 10.1021/acs.jmedchem.7b00967. Epub 2018 May 24. PMID: 29763564.
25
26. Lee SY, Baek N, Nam TG. Natural, semisynthetic and synthetic tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2016;31(1):1-13. doi: 10.3109/14756366.2015.1004058. Epub 2015 Feb 16. PMID: 25683082.
26
27. Tan X, Song YH, Park C, Lee KW, Kim JY, Kim DW, Kim KD, Lee KW, Curtis-Long MJ, Park KH. Highly potent tyrosinase inhibitor, neorauflavane from Campylotropis hirtella and inhibitory mechanism with molecular docking. Bioorg Med Chem. 2016 Jan 15;24(2):153-9. doi: 10.1016/j.bmc.2015.11.040.
27
28. Hu X, Wang M, Yan GR, Yu MH, Wang HY, Hou AJ. 2-Arylbenzofuran and tyrosinase inhibitory constituents of Morus notabilis. J Asian Nat Prod Res. 2012;14(12):1103-8. doi: 10.1080/10286020.2012.724400.
28
29. Zhu JJ, Yan GR, Xu ZJ, Hu X, Wang GH, Wang T, Zhu WL, Hou AJ, Wang HY. Inhibitory Effects of (2'R)-2',3'-dihydro-2'-(1-hydroxy-1-methylethyl)-2,6'-bibenzofuran-6,4'-diol on Mushroom Tyrosinase and Melanogenesis in B16-F10 Melanoma Cells. Phytother Res. 2015 Jul;29(7):1040-5. doi: 10.1002/ptr.5344.
29
30. Okombi S, Rival D, Bonnet S, Mariotte AM, Perrier E, Boumendjel A. Discovery of benzylidenebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes. J Med Chem. 2006 Jan 12;49(1):329-33. doi: 10.1021/jm050715i.
30
31. Jung HJ, Noh SG, Park Y, et al. In vitro and in silico insights into tyrosinase inhibitors with (E)-benzylidene-1-indanone derivatives. Comput Struct Biotechnol J. 2019;17:1255-1264. Published 2019 Aug 1. doi:10.1016/j.csbj.2019.07.017
31
32. Messerschmidt A. Copper Metalloenzymes. Comprehensive Natural Products II: Chem.Bio. 2010;8:489-545.
32
ORIGINAL_ARTICLE
Investigation of Chemical Composition of Oriental plane (Platanus orientalis L.) Hydrosol and its Effects on Tissue Damage Markers and Plasma Enzymes in Short-term Consumption
Oriental plane hydrosol (distillate), as a remedy for weight gain and asthma treatment is popular in ethnomedicine. Phytochemicals of medicinal plants could have side effects or serious damages. In this study, the oriental plane hydrosol was prepared by steam distillation. Also, tree oriental plane hydrosol samples from different companies were purchased from herbal market to compare the constituents. The phytochemicals in hexane and chloroform extracts of the hydrosols were identified by GC-MS analysis. In order to investigate subacute toxicity, the hydrosol was given to groups of 6 of male mice at doses of 10, 50, 100, 300 or 500 µl/ mouse/ twice a day by gavage for 14 consecutive days (subacute toxicity) or just for one day (acute toxicity). Serologic and pathologic samples were prepared. Chloroform extracts contained mostly (Z) -3-hexenol, thymol, carvacrol, camphor and the main constituents of hexane extracts include decane, dodecane and hexadecane. The results showed lack of serologic toxicity in subacute consumption of the hydrosol. In acute toxicity study, the levels of ALT, LDH, and BUN increased significantly. Other enzymes did not change significantly in compare to the control group. No significant pathologic damage was seen in heart or lung tissues, but the liver and kidney showed mild inflammation in acute toxicity study and inflammation in subacute toxicity studies. Determination of compounds which are responsible for the observed effects and especially safety of this hydrosol consumption for the longer periods can prevent side effects or possible toxicities.
https://tips.sums.ac.ir/article_47132_24c2bcbddb1384865ee0ead59c17f612.pdf
2020-12-01
243
254
10.30476/tips.2020.88485.1069
Aromatic water
Oriental Plane Distillate
Platanus orientalis
Toxicity
Reza
Heidari
reza.heidari@hotmail.com
1
Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Akbar
Raeisi
reisi@sums.ac.ir
2
Student research committee, School of pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Ardalan
Pasdaran
pasdaran@sums.ac.ir
3
Medicinal Plants Processing Research Center, Department of Pharmacognosy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Azadeh
Hamedi
hamediaz@sums.ac.ir
4
Department of Pharmacognosy, School of Pharmacy, Shiraz Unicersity of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
1. Thai QD, Tchoumtchoua J, Makropoulou M, Boulaka A, Meligova AK, Mitsiou DJ, Mitakou S, Michel S, Halabalaki M, Alexis MN, Skaltsounis LA. Phytochemical study and biological evaluation of chemical constituents of Platanus orientalis and Platanus × acerifolia buds. Phytochemistry. 2016 Oct;130:170-81. doi: 10.1016/j.phytochem.2016.04.006. Epub 2016 May 11. PMID: 27179684.
1
2. Haider S, Nazreen S, Alam MM, Hamid H, Alam MS. Anti-inflammatory and anti-nociceptive activities of Platanus orientalis Linn. and its ulcerogenic risk evaluation. J Ethnopharmacol. 2012 Aug 30;143(1):236-40. doi: 10.1016/j.jep.2012.06.029. Epub 2012 Jul 6. PMID: 22771315.
2
3. Aghili M. Gharabadin Kabir (Republished by Institute of Medical History, Islamic and Complementary Medicine). Iran University Of Medical Sciencess, Tehran, Iran. 2008.
3
4. Mahdizadeh S, Khaleghi Ghadiri M, Gorji A. Avicenna's Canon of Medicine: a review of analgesics and anti-inflammatory substances. Avicenna J Phytomed. 2015;5(3):182-202.
4
5. Torkan S, Mohajeri N, Khamesipour F. A comparison study of anti food allergy of plane tree leaves extract with the chemical drug therapy in affected dogs. Marmara Pharm J. 2016;20:86-91.
5
6. Tantry MA, Akbar S, Dar JA, Irtiza S, Galal A, Khuroo MA, et al. Acylated flavonol glycoside from Platanus orientalis. Fitoterapia. 2012;83(2):281-5.
6
7. Yang C-H, Yang Y, Liu J-H. Platachromone A–D: Cytotoxic 2-styrylchromones from the bark of Platanus× acerifolia (Aiton) Willd. Phytochemistry Letters. 2013;6(3):387-91.
7
8. Pazouki N, Sankian M, Nejadsattari T, Khavari-Nejad RA, Varasteh AR. Oriental plane pollen allergy: identification of allergens and cross-reactivity between relevant species. Allergy Asthma Proc. 2008 Nov-Dec;29(6):622-8. doi: 10.2500/aap.2008.29.3178. PMID: 19173789.
8
9. Pazouki N, Sankian M, Leung PT, Nejadsattari T, Khavari-Nejad RA, Varasteh AR. Identification of cyclophilin as a novel allergen from Platanus orientalis pollens by mass spectrometry. J Biosci Bioeng. 2009 Feb;107(2):215-7. doi: 10.1016/j.jbiosc.2008.10.016. PMID: 19217563.
9
10. Mirsadraee M, Tavakoli A, Ghorani V, Ghaffari S. Effects of Rosmarinus officinalis and Platanus orientalis extracts on asthmatic subjects resistant to routine treatments. Avicenna J Phytomed. 2018 Sep-Oct;8(5):399-407. PMID: 30345227; PMCID: PMC6190250.
10
11. Chatzigeorgiou S, Thai QD, Tchoumtchoua J, Tallas K, Tsakiri EN, Papassideri I, Halabalaki M, Skaltsounis AL, Trougakos IP. Isolation of natural products with anti-ageing activity from the fruits of Platanus orientalis. Phytomedicine. 2017 Sep 15;33:53-61. doi: 10.1016/j.phymed.2017.07.009. Epub 2017 Jul 31. PMID: 28887920.
11
12. SICAK Y, Eliuz EAE. Determination of the phytochemical profile, in vitro the antioxidant and antimicrobial activities of essential oil from Arbutus andrachne L. wood growing in Turkey. Türkiye Ormancılık Dergisi. 2019;20(1):57-61.
12
13. Dogan A, Anuk OO. Investigation of the phytochemical composition and antioxidant properties of chinar (Platanus orientalis L.) leaf infusion against ethanol-induced oxidative stress in rats. Mol Biol Rep. 2019 Jun;46(3):3049-3061. doi: 10.1007/s11033-019-04741-7. Epub 2019 Mar 12. PMID: 30864112.
13
14. Hajhashemi V, Ghannadi A, Mousavi S. Antinociceptive study of extracts of Platanus orientalis leaves in mice. Res Pharm Sci. 2011 Jul;6(2):123-8. PMID: 22224096; PMCID: PMC3249775.
14
15. Hamedi A, Pasdaran A, Zebarjad Z, Moein M. A Survey on Chemical Constituents and Indications of Aromatic Waters Soft Drinks (Hydrosols) Used in Persian Nutrition Culture and Folk Medicine for Neurological Disorders and Mental Health. J Evid Based Complementary Altern Med. 2017 Oct;22(4):744-752. doi: 10.1177/2156587217714145. Epub 2017 Jun 21. PMID: 28633539; PMCID: PMC5871290.
15
16. Hamedi A, Moheimani SM, Sakhteman A, Etemadfard H, Moein M. An Overview on Indications and Chemical Composition of Aromatic Waters (Hydrosols) as Functional Beverages in Persian Nutrition Culture and Folk Medicine for Hyperlipidemia and Cardiovascular Conditions. J Evid Based Complementary Altern Med. 2017 Oct;22(4):544-561. doi: 10.1177/2156587216686460. Epub 2017 Feb 9. PMID: 29228785; PMCID: PMC5871258.
16
17. Hamedi A, Afifi M, Etemadfard H. Investigating Chemical Composition and Indications of Hydrosol Soft Drinks (Aromatic Waters) Used in Persian Folk Medicine for Women's Hormonal and Reproductive Health Conditions. J Evid Based Complementary Altern Med. 2017 Oct;22(4):824-839. doi: 10.1177/2156587217717413.
17
18. Heidari R, Niknahad H, Sadeghi A, Mohammadi H, Ghanbarinejad V, Ommati MM, et al. Betaine treatment protects liver through regulating mitochondrial function and counteracting oxidative stress in acute and chronic animal models of hepatic injury. Biomed Pharmacother. 2018 Jul;103:75-86. doi: 10.1016/j.biopha.2018.04.010. Epub 2018 Apr 7. PMID: 29635131.
18
19. Hamedi A, Jamshidzadeh A, Dana M, Pasdaran A, Heidari R. Effects of the essential oil from Citrus aurantium flowers on liver health parameters in a laboratory animal model. Feyz. 2020;24(1):38-47
19
20. Hatanaka A, Sekiya J, Kajiwara T. Distribution of an enzyme system producing cis-3-hexenal and n-hexanal from linolenic and linoleic acids in some plants. Phytochemistry. 1978;17(5):869-72.
20
21. Tollsten L, Bergström G. Headspace volatiles of whole plants and macerated plant parts of Brassica and Sinapis. Phytochemistry. 1988;27(7):2073-7.
21
22. Remaud G, Debon AA, Martin Y-l, Martin GG, Martin GJ. Authentication of bitter almond oil and cinnamon oil: application of the SNIF-NMR method to benzaldehyde. J Agric Food Chem. 1997;45(10):4042-8.
22
23. Kula J, Sadowska H. One-pot synthesis of (E)-2-nonenal from castor oil. J Am Oil Chem Soc. 1993;70(6):643-4.
23
24. Tigrine-Kordjani N, Meklati BY, Chemat F. Contribution of microwave accelerated distillation in the extraction of the essential oil of Zygophyllum album L. Phytochem Anal. 2011 Jan-Feb;22(1):1-9. doi: 10.1002/pca.1236. Epub 2010 Sep 7. PMID: 20821807.
24
25. Tieman DM, Zeigler M, Schmelz EA, Taylor MG, Bliss P, Kirst M, Klee HJ. Identification of loci affecting flavour volatile emissions in tomato fruits. J Exp Bot. 2006;57(4):887-96. doi: 10.1093/jxb/erj074. Epub 2006 Feb 10. PMID: 16473892.
25
26. Pourmortazavi SM, Ghadiri M, Hajimirsadeghi SS. Supercritical fluid extraction of volatile components from Bunium persicum Boiss.(black cumin) and Mespilus germanica L.(medlar) seeds. J Food Compost Anal. 2005;18(5):439-46.
26
27. Memon A, Memon N, Luthria D, Pitafi A, Bhanger M. Phenolic compounds and seed oil composition of Ziziphus mauritiana L. fruit. Polish J Food Nutr Sci. 2012;62(1):15-21.
27
28. Öztürk M, Aydoğmuş-Öztürk F, Duru ME, Topçu G. Antioxidant activity of stem and root extracts of Rhubarb (Rheum ribes): An edible medicinal plant. Food Chem. 2007;103(2):623-30.
28
29. Kawase T, Kato S, Lieber CS. Lipid peroxidation and antioxidant defense systems in rat liver after chronic ethanol feeding. Hepatology. 1989 Nov;10(5):815-21. doi: 10.1002/hep.1840100511. PMID: 2807160.
29
ORIGINAL_ARTICLE
Preparation and Characterization of Berberine loaded Micelle Formulations with Approach to Oral Drug Delivery
Berberine (BBR) is a quaternary ammonium salt that possesses plentiful therapeutics properties. But notwithstanding the positive points, it has two negative points: poor aqueous solubility and permeability. These properties are important for achieving good bioavailability and therapeutic effect. Lately nano formulations developed to overcome these challenges through drug encapsulation. The aim of this study was preparation of nano formulations based on surfactant to achieve the best formulation with good characteristics. In this research, nano micellar formulations were prepared by thin film hydration method using poly sorbate 20 as surfactant and BBR as drug to get the good formulation based on high encapsulation efficiency (EE). Then nano micelles were characterized by particle size and polydispersity index (PDI) by DLS, drug encapsulation by UV-Vis spectrophotometer and drug release behavior in simulated gastro fluid (SGF) and simulated intestinal fluid (SIF). BBR successfully was encapsulated within micelles by thin film hydration method. DLS analysis showed average size of nano micelle samples between 9.247 and 18.46 nm, PDI was about 0.271, with maximum percentage of drug encapsulation of 78%. Also fluctuation of drug release was very low in elementary time points in SGF and SIF, and it was approximately sustained release profile. These results showed to achieve a good formulation and in order to have better drug delivery, physical attributes including the size distribution, PDI, and EE should be controlled. Our findings may be benefactress for different applications in variety research fields of pharmaceutical industry.
https://tips.sums.ac.ir/article_47269_f453977f63c9690de8e4341116ee2f33.pdf
2020-12-01
255
262
10.30476/tips.2021.88569.1070
berberine
nano formulation
Drug delivery
encapsulation
micelle
Roza
Azadi
azadiroza900@gmail.com
1
Department of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
AUTHOR
Seyyedeh Elaheh
Musavi
semousavi@sina.tums.ac.ir
2
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Negar
Motekef
negar.motakef@gmail.com
3
Department of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
AUTHOR
Seyed Mehdi
Rezayat
rezayat@sina.tums.ac.ir
4
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mahmoudreza
Jafari
jafarimr@mums.ac.ir
5
Department of Pharmaceutical Nanotechnology, Mashhad University of Medical Sciences, Mashhad, Iran.
AUTHOR
1. Homayun B, Lin X, Choi HJ. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics. 2019 Mar 19;11(3):129. doi: 10.3390/pharmaceutics11030129.
1
2. Ma S, Wang L, Huang X, Wang X, Chen S, Shi W, Qiao X, Jiang Y, Tang L, Xu Y, Li Y. Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus. Microb Cell Fact. 2018 Feb 9;17(1):20. doi: 10.1186/s12934-018-0861-7.
2
3. Kwon K, Daniell H. Oral delivery of protein drugs bioencapsulated in plant cells. Mol Ther. 2016; 24: 1342-50.
3
4. Pund S, Borade G, Rasve G. Improvement of anti-inflammatory and anti-angiogenic activity of berberine by novel rapid dissolving nanoemulsifying technique. Phytomedicine. 2014 Feb 15;21(3):307-14. doi: 10.1016/j.phymed.2013.09.013.
4
5. Singh N, Sharma B. Toxicological Effects of Berberine and Sanguinarine. Front Mol Biosci. 2018 Mar 19;5:21. doi: 10.3389/fmolb.2018.00021.
5
6. Fan D, Liu L, Wu Z, Cao M. Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. Curr Neuropharmacol. 2019;17(6):563-579. doi:10.2174/1570159X16666180419141613
6
7. Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med. 2014;2014:289264. doi: 10.1155/2014/289264.
7
8. Xu JH, Liu XZ, Pan W, Zou DJ. Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. Mol Med Rep. 2017;15(5):2765-2787. doi:10.3892/mmr.2017.6321
8
9. Zou K, Li Z, Zhang Y, et al. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin. 2017;38(2):157-167. doi:10.1038/aps.2016.125
9
10. Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI, Crişan G, Buzoianu AD. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front Pharmacol. 2018 Aug 21;9:557. doi: 10.3389/fphar.2018.00557.
10
11. Yuan NN, Cai CZ, Wu MY, Su HX, Li M, Lu JH. Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies. BMC Complement Altern Med. 2019 May 23;19(1):109. doi: 10.1186/s12906-019-2510-z.
11
12. Hasanein P, Ghafari-Vahed M, Khodadadi I. Effects of isoquinoline alkaloid berberine on lipid peroxidation, antioxidant defense system, and liver damage induced by lead acetate in rats. Redox Rep. 2017 Jan;22(1):42-50. doi: 10.1080/13510002.2016.1140406.
12
13. Sahibzada MUK, Sadiq A, Faidah HS, Khurram M, Amin MU, Haseeb A, Kakar M. Berberine nanoparticles with enhanced in vitro bioavailability: characterization and antimicrobial activity. Drug Des Devel Ther. 2018 Feb 14;12:303-312. doi: 10.2147/DDDT.S156123.
13
14. Cui HX, Hu YN, Li JW, Yuan K, Guo Y. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. Molecules. 2018 Dec 28;24(1):103. doi: 10.3390/molecules24010103.
14
15. Liu CS, Zheng YR, Zhang YF, Long XY. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016 Mar;109:274-82. doi: 10.1016/j.fitote.2016.02.001.
15
16. Kumar A, Ekavali, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. Current knowledge and pharmacological profile of berberine: An update. Eur J Pharmacol. 2015 Aug 15;761:288-97. doi: 10.1016/j.ejphar.2015.05.068.
16
17. Ye M, Fu S, Pi R, He F. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J Pharm Pharmacol. 2009 Jul;61(7):831-7. doi: 10.1211/jpp/61.07.0001.
17
18. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71. doi: 10.1186/s12951-018-0392-8.
18
19. Lu Y, Yue Z, Xie J, Wang W, Zhu H, Zhang E, Cao Z. Micelles with ultralow critical micelle concentration as carriers for drug delivery. Nat Biomed Eng. 2018 May;2(5):318-325. doi: 10.1038/s41551-018-0234-x.
19
20. Long JA, Rankin BM, Ben-Amotz D. Micelle Structure and Hydrophobic Hydration. J Am Chem Soc. 2015 Aug 26;137(33):10809-15. doi: 10.1021/jacs.5b06655.
20
21. Santos M, Tavares F, Biscaia E. molecular thermodynamics of micellization: micelle size distributions and geometry transitions. Braz J Chem Eng. 2016; 33(3): 515-523. doi.org/10.1590/0104-6632.20160333s20150129.
21
22. Lu Y, Zhang E, Yang J, Cao Z. Strategies to improve micelle stability for drug delivery. Nano Res. 2018 Oct;11(10):4985-4998. doi: 10.1007/s12274-018-2152-3.
22
23. Yang T, Li W, Duan X, et al. Preparation of Two Types of Polymeric Micelles Based on Poly(β-L-Malic Acid) for Antitumor Drug Delivery. PLoS One. 2016;11(9):e0162607. Published 2016 Sep 20. doi:10.1371/journal.pone.0162607
23
24. Hanafy NAN, El-Kemary M, Leporatti S. Micelles Structure Development as a Strategy to Improve Smart Cancer Therapy. Cancers (Basel). 2018;10(7):238. Published 2018 Jul 20. doi:10.3390/cancers10070238
24
25. Mandal A, Bisht R, Rupental L, Mitra A. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release. 2017; 248: 96–116, doi: 10.1016/j.jconrel.2017.01.012.
25
26. Adrion AC, Nakamura J, Shea D, Aitken MD. Screening Nonionic Surfactants for Enhanced Biodegradation of Polycyclic Aromatic Hydrocarbons Remaining in Soil After Conventional Biological Treatment. Environ Sci Technol. 2016 Apr 5;50(7):3838-45. doi: 10.1021/acs.est.5b05243.
26
27. Lv S, Wu Y, Cai K, He H, Li Y, Lan M, Chen X, Cheng J, Yin L. High Drug Loading and Sub-Quantitative Loading Efficiency of Polymeric Micelles Driven by Donor-Receptor Coordination Interactions. J Am Chem Soc. 2018 Jan 31;140(4):1235-1238. doi: 10.1021/jacs.7b12776.
27
28. Szymczyk K, Szaniawska M, Taraba A. Micellar Parameters of Aqueous Solutions of Tween 20 and 60 at Different Temperatures: Volumetric and Viscometric Study. Colloids Interfaces. 2018; 2: 34, doi:10.3390/colloids2030034.
28
29. Ai X, Zhong L, Niu H, He Zh. Thin-film hydration preparation method and stability test of DOX-loaded disulfide-linked polyethylene glycol 5000-lysine-di-tocopherol succinate nanomicelles. Asian J Pharm Sci. 2014; 9(5): 244-250, doi.org/10.1080/10837450.2017.1330345.
29
30. Rojsanga P, Gritsanapan W, Suntornsuk L. Determination of berberine content in the stem extracts of Coscinium fenestratum by TLC densitometry. Med Princ Pract. 2006;15(5):373-8. doi: 10.1159/000094272. PMID: 16888396.
30
31. Ebrahimi Nik M, Malaekeh-Nikouei B, Amin M, Hatamipour M, Teymouri M, Sadeghnia H.R, et al. Liposomal formulation of Galbanic acid improved therapeutic efcacy of pegylated liposomal Doxorubicin in mouse colon carcinoma. Sci Rep. 2019;9:9527. doi.org/10.1038/s41598-019-45974-7.
31
32. Hatamipour M, Sahebkar A, Alavizadeh SH, Dorri M, Jaafari MR. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iran J Basic Med Sci. 2019 Mar;22(3):282-289. doi: 10.22038/ijbms.2019.32873.7852.
32
33. Deepak Sh, Dipika M, Gilphy Ph, Ravish R, Shanu B, Manisha S, et al. Formulation and Optimization of Polymeric Nanoparticles for Intranasal Delivery of Lorazepam Using Box-Behnken Design: In Vitro and In Vivo Evaluation. BioMed Res Inter. 2014, 3:156010. doi: 10.1155/2014/156010.
33
34. Bahari L.A. Hamishehkar H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review. Adv Pharm Bull. 2016; 6 (2): 143. doi: 10.15171/apb.2016.021.
34
35. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari MR. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018 May 18;10(2):57. doi: 10.3390/pharmaceutics10020057.
35
36. Mantha S, Qi Sh, Barz M, Schemid F. How ill-defined constituents produce well-defined nanoparticles: Effect of polymer dispersity on the uniformity of copolymeric micelles. 2019;3(2), doi.org/10.1103/PhysRevMaterials.3.026002.
36
37. Maherani B, Wattraint O. Liposomal structure: A comparative study on light scattering and chromatography techniques. J Dispers Sci Technol. 2017;38:1633-9, doi.org/10.1080/01932691.2016.1269651.
37
38. International Standard ISO22412 Particle Size Analysis-Dynamic Light Scattering, International Organisation for Standardisation (ISO) 2008.
38
39. Ford J.L: Particle Size Analysis in Pharmaceutics and Other Industries: Theory and Practice. Ellis Horwood, England, 1993.
39
ORIGINAL_ARTICLE
Resveratrol abrogates 5-flourouracil -induced hepatotoxicity: A preclinical study
The manifestation of acute hepatotoxicity caused by 5-fluorouracil could be characterized by asymptomatic elevations of liver enzymes, hepatic steatosis and fuminant hepatitis. Natural antioxidants have potential as excellent treatment strategy against diseases and drug-induced toxicities. This study assessed the potential of resveratrol (RSV) to abrogate the hepatotoxic effect of 5-FU in rats. Forty adult male albino rats (240g± 20g) were randomized and orally supplemented with RSV (10, 20 and 40 mg/kg/day) prior to the administration of 5-FU (20mg/kg/day) intraperitoneally for 5 days. On day 6, after weighing, the rats were anesthetized, blood samples were collected and centrifuged and sera obtianed. Liver tissues were harvested and weighed. Sera and liver samples were evaluated for biochemical parameters. Liver tissues were assessed for histology. Body weight was significantly (p <0.05) decreased where as liver weight was significantly (p <0.01) increased in 5-FU administered rats in relation to control. Serum and liver lactate dehydrogenase, aminotransferases (AST), alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, conjugated bilirubin and malondialdehyde levels were significantly (p <0.001) increased in 5FU-administered rats in relation to control. Liver glutathione peroxidase, catalase, glutathione and superoxide dismutase levels were significantly (p <0.001) decreased in 5-FU administered rats in relation to control. The liver of 5-FU administered rats showed necrosis and steatosis. The hepatotoxic effect of 5-FU was abrogated in a dose-related fashion in RSV 10 mg/kg (p <0.05), 20mg/kg (p <0.01), and RSV 40mg/kg (p <0.001) supplemented rats in relation to 5-FU. RVS may be clinically effective against 5-FU-induced hepatotoxicity.
https://tips.sums.ac.ir/article_47251_7d188cfa203978a9d510db6fb450362f.pdf
2020-12-01
263
270
10.30476/tips.2021.87868.1065
5-Fluoroural
Liver
Toxicity
Resveratrol
Mitigation
Rat
Elias
Adikwu
adikwuelias@gmail.com
1
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University, Nigeria
LEAD_AUTHOR
Nelson
Ebinyo
ebinyonelson@yahoo.com
2
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University, Nigeria
AUTHOR
Clara
Clara Adogbo Ejovwoke
adikwuelias@yahoo.com
3
Department of Biochemistry, Faculty of Science, Madonna University Nigeria
AUTHOR
1. Yousef HN, Aboelwafa HR. The potential protective role of taurine against 5-fluorouracil-induced nephrotoxicity in adult male rats. Exp Toxicol Pathol. 2017 Jun 14;69(5):265-274. doi: 10.1016/j.etp.2017.01.012. Epub 2017 Feb 8. PMID: 28189472.
1
2. Nadia R.A. Abou-Zeid. Ameliorative effect of vitamin C against 5-fuorouracil-induced hepatotoxicity in mice: A light and electron microscope study. J Basic Appl Zool. 2014;67:109-18
2
3. Focaccetti C, Bruno A, Magnani E, Bartolini D, Principi E, Dallaglio K, Bucci EO, Finzi G, Sessa F, Noonan DM, Albini A. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One. 2015 Feb 11;10(2):e0115686. doi: 10.1371/journal.pone.0115686. PMID: 25671635; PMCID: PMC4324934.
3
4. Hajj A, Ghosn M, Mourad D, Hojaiban K, Mousallem P, Khabbaz LR. Lethal hepatotoxicity following 5-fluorouracil/cisplatin chemotherapy: a relevant case report. Per Med. 2017 May;14(3):197-201. doi: 10.2217/pme-2016-0085. Epub 2017 May 5. PMID: 29767581.
4
5. Fukuno S, Nagai K, Yoshida S, Suzuki H, Konishi H. Taurine as a protective agent for 5-fluorouracil-induced hepatic damage related to oxidative stress. Pharmazie. 2016 Sep 1;71(9):530-532. doi: 10.1691/ph.2016.6611. PMID: 29441849.
5
6. Ray S, Roy K, Sengupta C. In vitro evaluation of protective effects of ascorbic acid and water extract of Spirulina plantesis (blue green algae) on 5-fluorouracil-induced lipid peroxidation. Acta Pol Pharm. 2007 Jul-Aug;64(4):335-44. PMID: 18536159.
6
7. Gerszon J, Rodacka A, Puchała M. Antioxidant properties of resveratrol and its protective effects in neurodegenerative diseases. Med J Cell Biol. 2014;4:97-117.
7
8. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res. 2011 May 1;90(2):224-33. doi: 10.1093/cvr/cvr034. Epub 2011 Feb 1. PMID: 21285292.
8
9. Liu FC, Tsai YF, Tsai HI, Yu HP. Anti-Inflammatory and Organ-Protective Effects of Resveratrol in Trauma-Hemorrhagic Injury. Mediators Inflamm. 2015;2015:643763. doi: 10.1155/2015/643763. Epub 2015 Jul 26. PMID: 26273141; PMCID: PMC4529946.
9
10. Švajger U, Jeras M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol. 2012 Jun;31(3):202-22. doi: 10.3109/08830185.2012.665108. PMID: 22587021.
10
11. Xia N, Daiber A, Förstermann U, Li H. Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol. 2017;174(12):1633-1646. doi:10.1111/bph.13492
11
12. Singh D, Cho WC, Upadhyay G. Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview. Front Physiol. 2016 Jan 26;6:363. doi: 10.3389/fphys.2015.00363. PMID: 26858648; PMCID: PMC4726750.
12
13. Radwan OK, Ahmed RF. Amendment effect of resveratrol on diclofenac idiosyncratic toxicity: Augmentation of the anti-inflammatory effect by assessment of Arachidonic acid and IL-1β levels. J App Pharm Sci. 2016;6(12):170-7.
13
14. Gelen V, Şengül E, Yıldırım S, Atila G. The protective effects of naringin against 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats. Iran J Basic Med Sci. 2018 Apr;21(4):404-410. doi: 10.22038/IJBMS.2018.27510.6714. PMID: 29796225; PMCID: PMC5960758.
14
15. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302-10. doi: 10.1016/s0076-6879(78)52032-6. PMID: 672633.
15
16. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968 Oct 24;25(1):192-205. doi: 10.1016/0003-2697(68)90092-4. PMID: 4973948.
16
17. Sun M, Zigman S. An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Anal Biochem. 1978 Oct 1;90(1):81-9. doi: 10.1016/0003-2697(78)90010-6. PMID: 727489.
17
18. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-6. doi: 10.1016/s0076-6879(84)05016-3. PMID: 6727660.
18
19. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973 Feb 9;179(4073):588-90. doi: 10.1126/science.179.4073.588. PMID: 4686466.
19
20. El-Hoseany NMA. Protective effect of captopril against 5-fluorouracil-induced hepato and nephrotoxicity in male albino rats. J Am Sci. 2013;8:680-685
20
21. Thriveni V, Manjunatha H, Santhosh KH. Hepatoprotective Effect of Curcumin and Capsaicin against Lipopolysaccharide Induced Liver Damage in Mice. Pharmacog J. 2017;9(6):947-51.
21
22. Adikwu E, Nelson EC, Fiyebo P. Selenium as a therapeutic adjuvant for isoniazid/rifampicin‑induced hepatotoxicity. BLDE Univ J Health Sci. 2020;5:60-7.
22
23. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014 Sep;147(3):577-594.e1. doi: 10.1053/j.gastro.2014.06.043. Epub 2014 Jul 25. PMID: 25066692.
23
24. Dimitriu D, Lupusoru C, Cojocaru I, Gafitanu C, Palade L, Lupusoru R. Assessing biochemical andoxidative stress parameters after vaginal and oral administration of 5-fluorouracil in laboratory animals. Farmacia. 2015;63:230-3.
24
25. Adikwu E, Braimbaifa N, Obianime AW. Melatonin and Alpha Lipoic Acid: Possible Mitigants for Lopinavir/Ritonavir- Induced Renal Toxicity in Male Albino Rats. Physiol Pharmacol. 2016;19:232-40.
25
26. Behling EB, Sendão MC, Francescato HD, Antunes LM, Costa RS, Bianchi Mde L. Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys. Pharmacol Rep. 2006 Jul-Aug;58(4):526-32. PMID: 16963799.
26
27. Grotto D, Maria SL, Valentini J, Paniz C, Schmitt G, Garcia SC. Importance of the lipid peroxidation biomarkers and methodological aspects FOR malondialdehyde quantification. Quím. Nova. 2009;32(1):169-174.
27
28. El-Sayyad HI, Ismail MF, Shalaby FM, et al. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int J Biol Sci. 2009;5(5):466-473. Published 2009 Jun 28. doi:10.7150/ijbs.5.466
28
29. Gelen V, Şengül E, Gedikli S, Atila G, Uslu H, Makav M. The protective effect of rutin and quercetin on 5-FU-induced hepatotoxicity in rats. Asian Pac J Trop Biomed. 2017;7:647–653.
29
30. Al-Asmari AK, Khan AQ, Al-Masri N. Mitigation of 5-fluorouracil-induced liver damage in rats by vitamin C via targeting redox-sensitive transcription factors. Hum Exp Toxicol. 2016 Nov;35(11):1203-1213. doi: 10.1177/0960327115626583. Epub 2016 Jul 11. PMID: 26921358.
30
31. Almroth BC, Sturve J, Berglund A, Förlin L. Oxidative damage in eelpout (Zoarces viviparus), measured as protein carbonyls and TBARS, as biomarkers. Aquat Toxicol. 2005 Jun 15;73(2):171-80. doi: 10.1016/j.aquatox.2005.03.007. Epub 2005 Apr 13. PMID: 15917092.
31
32. Afolabi OK, Adeleke GE, Ugbaja RN. Crocin Alleviates 5-Fluorouracil-induced Hepatotoxicity through the abrogation of Oxidative Stress in Male Wistar rats. Asian Pac J Health Sci. 2016;3(2):58-68
32
33. Cordova-Gomez M, Galano A, Raul J, Alvarez-Idaboy JR. Piceatannol, a better peroxyl radical scavenger than resveratrol. RSC Adv. 2013;3:20209-20218
33
34. Kavas GO, Ayral PA, Elhan AH. The effects of resveratrol on oxidant/antioxidant systems and their cofactors in rats. Adv Clin Exp Med. 2013 Mar-Apr;22(2):151-5. PMID: 23709370.
34
35. KKincaid B, Bossy-Wetzel E. Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and neurodegeneration. Front Aging Neurosci. 2013;5:48. Published 2013 Sep 6. doi:10.3389/fnagi.2013.00048
35
36. Robb EL, Page MM, Wiens BE, Stuart JA. Molecular mechanisms of oxidative stress resistance induced by resveratrol: Specific and progressive induction of MnSOD. Biochem Biophys Res Commun. 2008 Mar 7;367(2):406-12. doi: 10.1016/j.bbrc.2007.12.138. Epub 2007 Dec 31. PMID: 18167310.
36
37. Tadolini B, Juliano C, Piu L, Franconi F, Cabrini L. Resveratrol inhibition of lipid peroxidation. Free Radic Res. 2000 Jul;33(1):105-14. doi: 10.1080/10715760000300661. PMID: 10826926.
37
ORIGINAL_ARTICLE
Antiplasmodial activity of Anchomanes difformis aqueous leaf extract on Plasmodium berghei infected mice
Challenges including treatment failure, cost, resistance, and adverse effects associated with antimalarial drugs have increased the use of medical plants as alternative treatment. Anchomanes difformis (A. difformis) is a multipurpose plant used traditionally for the treatment of a variety of ailments including malaria, but with a paucity of scientific evidence. This study assessed the antiplasmodial activity of A. difformis aqueous leaf extract (AEA) in Plasmodium berghei (P. berghei) infected mice. AEA (100, 200 and 400 mg/kg) was orally administered to P. berghei infected mice in the curative, suppressive and prophylactic groups. The untreated parasitized control (UPC) and the positive control were administered orally with normal saline (0.2mL) and chloroquine (CQ) (10mg/kg). After treatment, blood samples were analyzed for parasitamia level, hematological parameters and liver samples were evaluated for histology. Curative, suppressive and prophylactic studies showed that administered AEA decreased parasitamia levels and increased survival time in a dose-dependent fashion with significance at 200 mg/kg (p
https://tips.sums.ac.ir/article_46877_e01be9d9a0b0e61ea4a3c652a40b6b21.pdf
2020-12-01
271
278
10.30476/tips.2020.87005.1054
Anchomanes difformis
Antimalaria
Hematology
Liver
mice
Bensandy
Odeghe
bensandym@yahoo.com
1
Department of Biochemistry, Faculty of Science, Madonna University Nigeria
LEAD_AUTHOR
Elias
Adikwu
adikwuelias@gmail.com
2
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University, Nigeria
AUTHOR
Frances
John
adikwuelias@yahoo.com
3
Department of Biochemistry, Faculty of Science, Madonna University Nigeria
AUTHOR
1. Phillips RS. Current status of malaria and potential for control. Clin Microbiol Rev. 2001 Jan;14(1):208-26. doi: 10.1128/CMR.14.1.208-226.2001. PMID: 11148010; PMCID: PMC88970.
1
2. Greenwood B, Mutabingwa T. Malaria in 2002. Nature. 2002 Feb 7;415(6872):670-2. doi: 10.1038/415670a. PMID: 11832954.
2
3. Tabbabi A. Socio-economic Impact of Malaria in Africa. Acta Scie Microbiol. 2018;17: 2-34.
3
4. White NJ. Antimalarial drug resistance.
4
J Clin Invest. 2004;113(8):1084-1092. doi:10.1172/JCI21682
5
5. Taek MM, Prajogo B, Agil M. Ethnomedicinal Plants Used for the Treatment of Malaria in Malaka, West Timor . J Young Pharm. 2018; 10(2): 187-192
6
6. Agyare C, Dwobeng AS, Agyepong N, Boakye YD, Mensah KB, Ayande PG, Adarkwa-Yiadom M. Antimicrobial, Antioxidant, and Wound Healing Properties of Kigelia africana (Lam.) Beneth. and Strophanthus hispidus DC. Adv Pharmacol Sci. 2013;2013:692613. doi: 10.1155/2013/692613. Epub 2013 Apr 11. PMID: 23662099; PMCID: PMC3639673.
7
7. Plowman T. Folk uses of New World aroids. Econ Bot. 1969;23:97-122.
8
8. Tchiakpe L, Balansard G, Bernard P, Dalziel JM. The useful plants of west tropical Africa. Planta Med, 1979; 39: 257.
9
9. Oyetayo VO. Comparative Studies of the Phytochemical and Antimicrobial Properties of the Leaf, Stem and Tuber of Anchomanes difformis.
10
J Pharm Toxicol. 2007;2:407-10.
11
10. Dalziel JM (1937) The useful plants of West Tropical Africa. The Crown Agents for the Colonies, London. pp. 52-560.
12
11. Akah P, Njike HA. Some pharmacological effects of rhizome aqueous extract of Anchomanes difformis. Fitoterapia 61. 1990:368-70.
13
12. Harborne J B. Phytochemical Methods. Chapman and Hall Ltd., London; 1973; 49:180-188.
14
13. Trease G and Evans W C. Pharmacognosy. Bailliere Tindall, London, Ed. 2008; 11, 45-50.
15
14. Knight DJ, Mamalis P, Peters W. The antimalarial activity of N-benzyl-oxydihydrotriazines. III. The activity of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(2,4,5,-trichloropropyloxy)-1,3,5-triazine hydrobromide (BRL 51084) and hydrochloride (BRL 6231). Ann Trop Med Parasitol. 1982 Feb;76(1):1-7. PMID: 7044322.
16
15. Lorke D. A new approach to practical acute toxicity testing. Arch Toxicol. 1983 Dec;54(4):275-87. doi: 10.1007/BF01234480. PMID: 6667118.
17
16. Ryley JF, Peters W. The antimalarial activity of some quinolone esters. Ann Trop Med Parasitol. 1970 Jun;64(2):209-22. doi: 10.1080/00034983.1970.11686683.
18
17. Peters, W. Rational methods in the search for antimalarial drugs. Trans R Soc Trop Med Hyg. 1967;61:400-10.
19
18. Mahady GB. Medicinal plants for the prevention and treatment of bacterial infections. Curr Pharm Des. 2005;11(19):2405-27. doi: 10.2174/1381612054367481. PMID: 16026296.
20
19. Ahmed H. A Anchomanes difformis: A Multipurpose Phytomedicine IOSR. J Pharm Biol Sci. 2018; 13; 2; 62-65
21
20. Bello OM, Jagaba SM, Bello OE. A wild edible vegetable Anchomanes difformis (Blume) Engl.: its ethnomedicinal, phytochemistry, nutritional importance and other uses. Eurasia J Biosci. 2019;13:1137-47.
22
21. Olanlokun JO, Babarinde CO and Olorunsogo O. O. Toxicity of Anchomanes difformis, An Antimalarial Herb in Murine Models. Eur Jour of Med Plants. 2017;20(3):1-13
23
22. Sullivan DJ Jr, Matile H, Ridley RG, Goldberg DE. A common mechanism for blockade of heme polymerization by antimalarial quinolines. J Biol Chem. 1998 Nov 20;273(47):31103-7. doi: 10.1074/jbc.273.47.31103. PMID: 9813011.
24
23. O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin--the debate continues. Molecules. 2010 Mar 12;15(3):1705-21. doi: 10.3390/molecules15031705. PMID: 20336009; PMCID: PMC6257357.
25
24. Iribhogbe OI, Agbaje EO, Oreagba IA, Aina O, Ota AD. Oxidant versus Antioxidant Activity in Malaria: Role of Nutritional Therapy. J Med Sci. 2012;12:229-33.
26
ORIGINAL_ARTICLE
The association between Helicobacter pylori eradication in peptic ulcer patients and gastric cancer? Investigation in an East-Asian population
H. pylori is Gram-negative, microaerophilic, and motile bacteria which colonized in human stomach of nearly 50% of world population; there are several evidence for chronic colonization with H. pylori that significantly increased the risk of gastric cancer development (15). Eradication of H. pylori infection can have reduced the risk of gastric cancer as well as reduction of H. pylori in young population as reservoir of infection (5,10). According to literatures, the mother to child transmission is predominant rout of H. pylori transmission in Japanese population; therefore, eradication of H. pylori infection can be considered as appropriated strategy for reducing both of gastric cancer as well as H. pylori infection burden (16). There are several literatures in relation to efficacy of H. pylori eradication for prevention of gastric cancer development in asymptomatic carrier and patients with endoscopic resections (7,8); however, we evaluated the efficacy of H. pylori eradication in reduction of gastric cancer in patients with history of peptic ulcer. We are suggested that H. pylori infection should be eradicated in peptic ulcer patients in order to reducing the risk of develop to gastric cancer.
https://tips.sums.ac.ir/article_47253_70a10d04fab8c9b32b586c49176fcff6.pdf
2020-12-01
279
282
10.30476/tips.2021.89405.1074
Helicobacter pylori
peptic ulcer
Gastric Cancer
Asia
Meta-analysis
Masoud
Keikha
masoud.keykha90@gmail.com
1
Mashhad univ med sci
LEAD_AUTHOR
1. Keikha M. Is there a relationship between Helicobacter pylori vacA i1 or i2 alleles and development into peptic ulcer and gastric cancer? A meta-analysis study on an Iranian population. New Microbes New Infect. 2020 Jul 3;36:100726. doi: 10.1016/j.nmni.2020.100726. PMID: 32714559; PMCID: PMC7378689.
1
2. Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res. 1998 Oct 1;58(19):4255-9. PMID: 9766647.
2
3. Karbalaei M, Keikha M. Potential association between the hopQ alleles of Helicobacter pylori and gastrointestinal diseases: A systematic review and meta-analysis. Meta Gene. 2020:100816.
3
4. Nozaki K, Shimizu N, Ikehara Y, Inoue M, Tsukamoto T, Inada K, Tanaka H, Kumagai T, Kaminishi M, Tatematsu M. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci. 2003 Mar;94(3):235-9. doi: 10.1111/j.1349-7006.2003.tb01426.x. PMID: 12824915.
4
5. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 Sep 13;345(11):784-9. doi: 10.1056/NEJMoa001999. PMID: 11556297.
5
6. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004 Jan 14;291(2):187-94. doi: 10.1001/jama.291.2.187. PMID: 14722144.
6
7. TTerasawa T, Hamashima C, Kato K, Miyashiro I, Yoshikawa T, Takaku R, Nishida H. Helicobacterpylori eradication treatment for gastric carcinoma prevention in asymptomatic or dyspeptic adults: systematic review and Bayesian meta-analysis of randomised controlled trials. BMJ Open. 2019 Sep 20;9(9):e026002. doi: 10.1136/bmjopen-2018-026002. PMID: 31542733; PMCID: PMC6756423.
7
8. Sugimoto M, Murata M, Yamaoka Y. Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis. World J Gastroenterol. 2020;26(15):1820-1840. doi:10.3748/wjg.v26.i15.1820
8
9. Youssefi M, Tafaghodi M, Farsiani H, Ghazvini K, Keikha M. Helicobacter pylori infection and autoimmune diseases; Is there an association with systemic lupus erythematosus, rheumatoid arthritis, autoimmune atrophy gastritis and autoimmune pancreatitis? A systematic review and meta-analysis study. J Microbiol Immunol Infect. 2020 Aug 28:S1684-1182(20)30209-7. doi: 10.1016/j.jmii.2020.08.011. Epub ahead of print. PMID: 32891538.
9
10. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005 May;100(5):1037-42. doi: 10.1111/j.1572-0241.2005.41384.x. PMID: 15842576.
10
11. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007 Jan;42 Suppl 17:21-7. doi: 10.1007/s00535-006-1924-9. PMID: 17238021.
11
12. Mabe K, Takahashi M, Oizumi H, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?. World J Gastroenterol. 2009;15(34):4290-4297. doi:10.3748/wjg.15.4290
12
13. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009 Nov;137(5):1641-8.e1-2. doi: 10.1053/j.gastro.2009.07.060. Epub 2009 Aug 5. PMID: 19664631.
13
14. Take S, Mizuno M, Ishiki K, Hamada F, Yoshida T, Yokota K, Okada H, Yamamoto K. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol. 2015 Jun;50(6):638-44. doi: 10.1007/s00535-014-1004-5. Epub 2014 Oct 29. PMID: 25351555.
14
15. Karbalaei M, Khorshidi M, Sisakht-pour B, Ghazvini K, Farsiani H, Youssefi M, Keikha M, et al. What are the effects of IL-1β (rs1143634), IL-17A promoter (rs2275913) and TLR4 (rs4986790) gene polymorphism on the outcomes of infection with H. pylori within as Iranian population; A systematic review and meta-analysis. Gene Reports. 2020:100735.
15
16. Konno M, Yokota S, Suga T, Takahashi M, Sato K, Fujii N. Predominance of mother-to-child transmission of Helicobacter pylori infection detected by random amplified polymorphic DNA fingerprinting analysis in Japanese families. Pediatr Infect Dis J. 2008 Nov;27(11):999-1003. doi: 10.1097/INF.0b013e31817d756e. PMID: 18845980.
16
ORIGINAL_ARTICLE
Acute lymphoblastic leukemia in children: A short review
Acute lymphoblastic leukemia is as the most common childhood cancer. The definite etiology of childhood ALL is unknown. The pathogenesis of ALL is described as the disruption of lymphocyte proliferation and differentiation. The most common signs and symptoms of ALL are fever, hepatosplenomegaly, lymphadenopathy, pallor, and bleeding. Diagnosis is based on conducting complete blood cell, peripheral blood smear, bone marrow aspirate, immunophenotype, and cytogenetics tests. A number of demographic, clinical, and paraclinical characteristics of patients have been determined as prognostic factors. To select the appropriate treatment protocol, patients are risk stratified. In induction therapy, vincristine, corticosteroid, and asparaginase are given for the low- and standard risk groups and a four-drug induction therapy including vincristine, corticosteroid, asparaginase, and anthracycline are given for high- and very high-risk group for B cell ALL. The induction phase follow with post-induction courses including consolidation, interim maintenance, delayed intensification, and maintenance phases. ALL in pediatrics has a good prognosis and high cure rate.
https://tips.sums.ac.ir/article_47252_96fdfb17fe978b3ba431fe07bf540356.pdf
2020-12-01
283
296
10.30476/tips.2021.88938.1073
Acute Lymphoblastic Leukemia
children
Epidemiology
Etiology
Treatment
Raziyeh
Karamikhah
raziye.karamikhah@gmail.com
1
Department of Clinical Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Iman
Karimzadeh
karimzadehiman@yahoo.com
2
Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
1. Lanzkowsky P, Lipton JM, Fish JD. Lanskowsky's manual of pediatric hematology and oncology. 6th ed. London: Elsevier Science; 2016.
1
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-43.
2
3. Zeind CS, Carvalho GM. Pediatric malignancies. In: Henry DW, Kaiser NA, editors. Applied therapeutics : the clinical use of drugs. 11th ed. Philadelphia: Wolters Kluwer; 2018.
3
4. Farahmand M, Almasi-Hashiani A, Hassanzade J, Moghadami M. Childhood cancer epidemiology based on cancer registry's data of Fars province of Iran. Koomesh. 2011;13(1):8-13 [In Persian].
4
5. Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma. Leuk Lymphoma. 2013 Sep;54(9):2035-40. doi: 10.3109/10428194.2013.769218. Epub 2013 Feb 28. PMID: 23363221.
5
6. Bruwier A, Chantrain CF. Hematological disorders and leukemia in children with Down syndrome. Eur J Pediatr. 2012 Sep;171(9):1301-7. doi: 10.1007/s00431-011-1624-1. Epub 2011 Nov 24. PMID: 22113227.
6
7. Mrózek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct;23(5):991-1010, v. doi: 10.1016/j.hoc.2009.07.001. PMID: 19825449; PMCID: PMC3607311.
7
8. Hakeem A, Shiekh AA, Bhat GM, Lone AR. Prognostification of ALL by Cytogenetics. Indian J Hematol Blood Transfus. 2015;31(3):322-331. doi:10.1007/s12288-014-0483-0
8
9. Jastaniah W, Elimam N, Abdalla K, AlAzmi AA, Aseeri M, Felimban S. High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia. Leuk Res Rep. 2018;10:44-51. Published 2018 Oct 9. doi:10.1016/j.lrr.2018.10.001
9
10. Biggs JR, Zhang DE. Molecular basis of lymphoid and myeloid diseases. In: Coleman WB, Tsongalis GJ, editors. Molecular pathology: the molecular basis of human disease. 2 ed. London: Elsevier Science 2018. p. 299-328.
10
11. Naeim F, Rao N, Song SX, Grody WW. Lymphocytopenia and lymphocytosis. In: F. N, editor. Atlas of hematopathology: morphology, immunophenotype, cytogenetics, and molecular approaches. London: Academic Press; 2013. p. 627-33.
11
12. Tadmor T, Polliack A. Lymphopenia a simple prognostic factor in lymphoma and other cancers: why not use it more as a guide? Leuk Lymphoma. 2010 Oct;51(10):1773-4. doi: 10.3109/10428194.2010.508825. PMID: 20849382.
12
13. Rubnitz JE, Campbell P, Zhou Y, Sandlund JT, Jeha S, Ribeiro RC, Inaba H, Bhojwani D, Relling MV, Howard SC, Campana D, Pui CH. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer. 2013 Jun 1;119(11):2061-6. doi: 10.1002/cncr.28026. Epub 2013 Mar 1. PMID: 23456849; PMCID: PMC3862024.
13
14. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011 Jan;22(1):149-155. doi: 10.1093/annonc/mdq314. PMID: 20595450.
14
15. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer. 2008 Jan 15;112(2):407-15. doi: 10.1002/cncr.23168. PMID: 18058809.
15
16. Le Jeune C, Bertoli S, Elhamri M, Vergez F, Borel C, Huguet F, et al. Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leuk Lymphoma. 2014 Apr;55(4):855-62. doi: 10.3109/10428194.2013.813504. Epub 2013 Aug 5. PMID: 23786457.
16
17. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007 Feb 1;109(3):926-35. doi: 10.1182/blood-2006-01-024729. Epub 2006 Sep 26. PMID: 17003380; PMCID: PMC1785141.
17
18. Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012 Jul;97(7):1048-56. doi: 10.3324/haematol.2011.047613. Epub 2012 Jan 22. PMID: 22271901; PMCID: PMC3396677.
18
19. Society AC. Prognostic Factors in Childhood Leukemia (ALL or AML) 2020 [Available from: https://www.cancer.org/cancer/leukemia-in-children/detection-diagnosis-staging/prognostic-factors.html.
19
20. Whitehead VM, Vuchich MJ, Cooley LD, Lauer SJ, Mahoney DH, Shuster JJ, et al. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Leuk Lymphoma. 1998 Nov;31(5-6):507-19. doi: 10.3109/10428199809057610. PMID: 9922041.
20
21. Raimondi SC, Pui CH, Hancock ML, Behm FG, Filatov L, Rivera GK. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia. 1996 Feb;10(2):213-24. PMID: 8637229.
21
22. Whitehead VM, Payment C, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, et al. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 2001 Jul;15(7):1081-8. doi: 10.1038/sj.leu.2402165. PMID: 11455977.
22
23. Wojtuszkiewicz A, Peters GJ, van Woerden NL, Dubbelman B, Escherich G, Schmiegelow K, et al. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. J Hematol Oncol. 2015 May 29;8:61. doi: 10.1186/s13045-015-0158-9. PMID: 26022503; PMCID: PMC4455979.
23
24. Wells BG, L. ST, DiPiro JT, DiPiro CV. oncologic disorders. Pharmacotherpay handbook. 10th ed. New York: McGraw-Hill Education; 2017.
24
25. Amir AH, Soheil Z, Mehran K, Esmaeil K, Abolfazl M. Survival rate of childhood leukemia in shiraz, southern iran. Iran J Pediatr. 2013 Feb;23(1):53-8. PMID: 23550191; PMCID: PMC3574992.
25
26. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Jan;18(1):81-112. doi: 10.6004/jnccn.2020.0001. PMID: 31910389.
26
27. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020 Nov 1;105(11):2524-39. doi: 10.3324/haematol.2020.247031. PMID: 33054110; PMCID: PMC7604619.
27
28. Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PMID: 32247396.
28
29. Tran TH, Loh ML. Ph-like acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):561-566. doi:10.1182/asheducation-2016.1.561
29